GSGreta Sommerhäuser

Greta Sommerhäuser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Greta Sommerhäuser has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)

    by Arndt Stahler, Andreas J. Kind, Christine Sers, Soulafa Mamlouk, Lothar Müller, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Ludwig Fischer von Weikersthal, Greta Sommerhäuser, et al.

    Purpose:We evaluated additional mutations in RAS wild-type (WT) metastatic colorectal cancer (mCRC) as prognostic and predictive biomarkers for the efficacy of added panitumumab to a 5-fluorouracil plus folinic acid (FU/FA) maintenance as pre-specified analysis of the randomized PanaMa trial.Patients and Methods:Mutations (MUT) were identified using targeted next-generation sequencing (NGS; Illumina Cancer Hotspot Panel v2) and IHC. RAS/BRAF V600E/PIK3CA/AKT1/ALK1/ERBB2/PTEN MUT and HER2/neu overexpressions were negatively hyperselected and correlated with median progression-free survival (PFS) and overall survival (OS) since start of maintenance treatment, and objective response rates (ORR). Univariate/multivariate Cox regression estimated hazard ratios (HR) and 95% confidence intervals (CI).Results:202 of 248 patients (81.5%) of the full analysis set (FAS) had available NGS data: hyperselection WT, 162 (80.2%); MUT, 40 (19.8%). From start of maintenance therapy, hyperselection WT tumors were associated with longer median PFS as compared with hyperselection MUT mCRC (7.5 vs. 5.4 months; HR, 0.75; 95% CI, 0.52–1.07; P = 0.11), OS (28.7 vs. 22.2 months; HR, 0.53; 95% CI, 0.36–0.77; P = 0.001), and higher ORR (35.8% vs. 25.0%, P = 0.26). The addition of panitumumab to maintenance was associated with significant benefit in hyperselection WT tumors for PFS (9.2 vs. 6.0 months; HR, 0.66; 95% CI, 0.47–0.93; P = 0.02) and numerically also for OS (36.9 vs. 24.9 months; HR, 0.91; 95% CI, 0.61–1.36; P = 0.50), but not in hyperselection MUT tumors. Hyperselection status interacted with maintenance treatment arms in terms of PFS (P = 0.06) and OS (P = 0.009).Conclusions:Extended molecular profiling beyond RAS may have the potential to improve the patient selection for anti-EGFR containing maintenance regimens.

  • Open Access

    Supplementary Data 1 from Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)

    by Arndt Stahler, Andreas J. Kind, Christine Sers, Soulafa Mamlouk, Lothar Müller, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Ludwig Fischer von Weikersthal, Greta Sommerhäuser, et al.

  • Open Access

    Supplementary Data 1 from Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)

    by Arndt Stahler, Andreas J. Kind, Christine Sers, Soulafa Mamlouk, Lothar Müller, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Ludwig Fischer von Weikersthal, Greta Sommerhäuser, et al.

  • Open Access

    Data from Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)

    by Arndt Stahler, Andreas J. Kind, Christine Sers, Soulafa Mamlouk, Lothar Müller, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Ludwig Fischer von Weikersthal, Greta Sommerhäuser, et al.

    Purpose:We evaluated additional mutations in RAS wild-type (WT) metastatic colorectal cancer (mCRC) as prognostic and predictive biomarkers for the efficacy of added panitumumab to a 5-fluorouracil plus folinic acid (FU/FA) maintenance as pre-specified analysis of the randomized PanaMa trial.Patients and Methods:Mutations (MUT) were identified using targeted next-generation sequencing (NGS; Illumina Cancer Hotspot Panel v2) and IHC. RAS/BRAF V600E/PIK3CA/AKT1/ALK1/ERBB2/PTEN MUT and HER2/neu overexpressions were negatively hyperselected and correlated with median progression-free survival (PFS) and overall survival (OS) since start of maintenance treatment, and objective response rates (ORR). Univariate/multivariate Cox regression estimated hazard ratios (HR) and 95% confidence intervals (CI).Results:202 of 248 patients (81.5%) of the full analysis set (FAS) had available NGS data: hyperselection WT, 162 (80.2%); MUT, 40 (19.8%). From start of maintenance therapy, hyperselection WT tumors were associated with longer median PFS as compared with hyperselection MUT mCRC (7.5 vs. 5.4 months; HR, 0.75; 95% CI, 0.52–1.07; P = 0.11), OS (28.7 vs. 22.2 months; HR, 0.53; 95% CI, 0.36–0.77; P = 0.001), and higher ORR (35.8% vs. 25.0%, P = 0.26). The addition of panitumumab to maintenance was associated with significant benefit in hyperselection WT tumors for PFS (9.2 vs. 6.0 months; HR, 0.66; 95% CI, 0.47–0.93; P = 0.02) and numerically also for OS (36.9 vs. 24.9 months; HR, 0.91; 95% CI, 0.61–1.36; P = 0.50), but not in hyperselection MUT tumors. Hyperselection status interacted with maintenance treatment arms in terms of PFS (P = 0.06) and OS (P = 0.009).Conclusions:Extended molecular profiling beyond RAS may have the potential to improve the patient selection for anti-EGFR containing maintenance regimens.

  • Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)

    by Arndt Stahler, Andreas J. Kind, Christine Sers, Soulafa Mamlouk, Lothar Müller, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Ludwig Fischer von Weikersthal, Greta Sommerhäuser, et al.

    Purpose: We evaluated additional mutations in RAS wild-type (WT) metastatic colorectal cancer (mCRC) as prognostic and predictive biomarkers for the efficacy of added panitumumab to a 5-fluorouracil plus folinic acid (FU/FA) maintenance as pre-specified analysis of the randomized PanaMa trial. Patients and Methods: Mutations (MUT) were identified using targeted next-generation sequencing (NGS; Illumina Cancer Hotspot Panel v2) and IHC. RAS/BRAF V600E/PIK3CA/AKT1/ALK1/ERBB2/PTEN MUT and HER2/neu overexpressions were negatively hyperselected and correlated with median progression-free survival (PFS) and overall survival (OS) since start of maintenance treatment, and objective response rates (ORR). Univariate/multivariate Cox regression estimated hazard ratios (HR) and 95% confidence intervals (CI). Results: 202 of 248 patients (81.5%) of the full analysis set (FAS) had available NGS data: hyperselection WT, 162 (80.2%); MUT, 40 (19.8%). From start of maintenance therapy, hyperselection WT tumors were associated with longer median PFS as compared with hyperselection MUT mCRC (7.5 vs. 5.4 months; HR, 0.75; 95% CI, 0.52–1.07; P = 0.11), OS (28.7 vs. 22.2 months; HR, 0.53; 95% CI, 0.36–0.77; P = 0.001), and higher ORR (35.8% vs. 25.0%, P = 0.26). The addition of panitumumab to maintenance was associated with significant benefit in hyperselection WT tumors for PFS (9.2 vs. 6.0 months; HR, 0.66; 95% CI, 0.47–0.93; P = 0.02) and numerically also for OS (36.9 vs. 24.9 months; HR, 0.91; 95% CI, 0.61–1.36; P = 0.50), but not in hyperselection MUT tumors. Hyperselection status interacted with maintenance treatment arms in terms of PFS (P = 0.06) and OS (P = 0.009). Conclusions: Extended molecular profiling beyond RAS may have the potential to improve the patient selection for anti-EGFR containing maintenance regimens.


  • Open Access

    Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212)

    by Greta Sommerhäuser, Meinolf Karthaus, Annika Kurreck, Alexej Ballhausen, Johanna W. Meyer‐Knees, Stefan Fruehauf, Ullrich Graeven, Lothar Mueller, Alexander O. Koenig, Ludwig Fischer V. Weikersthal, et al.

    Despite molecular selection, patients (pts) with RAS wildtype mCRC represent a heterogeneous population including diversity in metastatic spread. We investigated metastatic patterns for their prognostic and predictive impact on maintenance therapy with 5‐fluorouracil/folinic acid ± panitumumab. The study population was stratified according to (1) number of involved metastatic sites (single vs multiple organ metastasis), liver‐limited disease vs (2) liver metastasis plus one additional site, and (3) vs liver metastasis plus ≥two additional sites. Kaplan‐Meier method and Cox regressions were used to correlate efficacy endpoints. Single organ metastasis was observed in 133 pts (53.6%) with 102 pts (41.1%) presenting with liver‐limited disease, while multiple organ metastases were reported in 114 pts (46.0). Multiple compared to single organ metastases were associated with less favorable PFS (HR 1.48, 95% CI 1.13‐1.93; P = .004) and OS (HR 1.37, 95% CI 0.98‐1.93; P = .068) of maintenance therapy. While metastatic spread involving one additional extrahepatic site was not associated with clearly impaired survival compared to liver‐limited disease, pts with liver metastasis plus ≥two additional sites demonstrated less favorable PFS (HR 1.92, 95% CI 1.30‐2.83; P < .001), and OS (HR 2.38, 95% CI 1.51‐3.76; P < .001) of maintenance therapy. Pmab‐containing maintenance therapy appeared active in both pts with multiple (HR 0.58; 95% CI, 0.39‐0.86; P = .006) as well as to a lesser numerical extent in pts with single organ metastasis (HR 0.83; 95% CI, 0.57‐1.21; P = .332; Interaction P = .183). These data may support clinical decisions when EGFR‐based maintenance therapy is considered.


  • Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)

    by Greta Sommerhäuser, Annika Kurreck, Alexander Beck, Uli Fehrenbach, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Mueller, Alexander O. Koenig, Ludwig F. V. Weikersthal, et al.


  • Health of children born to childhood cancer survivors: Participant characteristics and methods of the Multicenter Offspring Study

    by Greta Sommerhäuser, Anja Borgmann-Staudt, Ralph Schilling, Eva Frey, Jiri Hak, Veronika Janhubová, Katerina Kepakova, Tomas Kepak, Stephanie Klco-Brosius, Maryna Krawczuk-Rybak, et al.


  • Vaccinations and Screening Examinations – Prevention Awareness Among Children of Childhood Cancer Survivors in Germany

    by Theresa Schuster, Anja Borgmann-Staudt, Charlotte Jessica König, Greta Sommerhäuser, Elisabeth Korte, Heike Hölling, Ralph Schilling, Magdalena Balcerek

    Background Immunisation levels and attendance of preventive screening examinations indicate primary health prevention awareness. We investigated participation among German childhood cancer survivors’ (CCS’) offspring in our national offspring study. Patients and methods CCS with biological children were surveyed on their offspring’s vaccination levels and attendance of preventive screening examinations by questionnaire. Data from the German general population was available for matched-pair analysis (KiGGS study, Robert Koch-Institute, n=17,641). Results Overall, 852/1,299 (65,6%) CCS completed 1,340 questionnaires regarding their childrenʼs health. In comparison with the general population, coverage of tetanus, diphtheria and pertussis inoculations were similar (tetanus 99,1 vs. 98,4%). Measles, mumps and rubella vaccinations were carried out significantly more often by CCS’ offspring (rubella 96,1 vs. 91,7%). Throughout all age groups, preventive screening examinations were attended significantly more often by CCS’ offspring. Parentʼs anxiety regarding their offspring’s health was identified to be a confounding variable for vaccination rates. Discussion and conclusion CCS’ offspring showed comparable to significantly higher participation levels of recommended vaccinations and screening examinations than their peers from the German general population. In contrast to the general population the attendance of CCS’ offspring did not decrease with rising age. CCS’ own experiences and increased worry about their children’s health may lead to a higher prevention awareness. This should be considered in counselling parents with a cancer history. Hintergrund Impfraten und Teilnahme an Vorsorgeuntersuchungen sind ein Indikator für das Bewusstsein für Gesundheitsprävention. Wir untersuchten die Teilnahme von Kindern ehemaliger Krebspatienten in einer deutschlandweiten Studie. Patienten und Methoden Ehemalige kinderonkologische Patienten wurden zur Inanspruchnahme von Impfungen und Vorsorgeuntersuchungen ihrer leiblichen Kinder befragt. Daten aus der deutschen Allgemeinbevölkerung standen für einen Vergleich per Matched-pair Analyse zur Verfügung (KiGGS-Basiserhebung, Robert Koch-Instituts, n=17,641). Ergebnisse Insgesamt beantworteten 852/1,299 (65,6%) ehemalige Patienten 1,340 Fragebögen zur Gesundheit ihrer Kinder. Die Impfquoten für Tetanus, Diphtherie und Keuchhusten entsprachen denen der deutschen Allgemeinbevölkerung (Tetanus 99,1 vs. 98,4%). Impfungen gegen Mumps, Masern und Röteln wurden signifikant häufiger bei Kindern ehemaliger Patienten durchgeführt (Röteln 96,1 vs. 91,7%). Vorsorgeuntersuchungen wurden signifikant häufiger in Anspruch genommen. Als Einflussfaktor für die erhöhten Impfraten wurde die Sorge der Eltern vor Gesundheitsbeeinträchtigungen der Nachkommen identifiziert. Diskussion und Schlussfolgerung Die Nachkommen ehemaliger kinderonkologischer Patienten nahmen Impfungen und Vorsorgeuntersuchungen signifikant häufiger in Anspruch. Im Unterschied zur Allgemeinbevölkerung nahm die Teilnahme an den Vorsorgeuntersuchungen nicht mit zunehmendem Alter der Kinder ab. Die eigenen Erfahrungen und die erhöhte Sorge um die Gesundheit der Nachkommen könnte zu einem erhöhten Präventions- und Früherkennungsbewusstsein bei den Eltern geführt haben. Dies sollte in der Beratung bei Eltern mit Krebserkrankung berücksichtigt werden.